ClinicalTrials.gg
Active, not recruitingNCT06624085Updated Oct 6, 2026

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 1 interventional study of Glofitamab and Tocilizumab in Lymphoma, sponsored by Hoffmann-La Roche. Active, not recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Updated Oct 6, 2026Now Active, not recruiting9 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing gemcitabine in Lymphoma — 1 open to participants now, 3 under way, none of them phase 3. Gemcitabine · Lymphoma.

Planned enrollment
19th of 40
50 · median 40
Started
2025
the only one that year
Phase 1
7 of 41
none open now
Registered
40th of 41
by date

Among the 41 studies testing gemcitabine in Lymphoma, this one is the 19th largest by planned enrollment of the 40 interventional ones that give a count, is the only one that started in 2025, is one of 7 in phase 1, and was the 40th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 41 studies testing gemcitabine in Lymphoma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing gemcitabine in Lymphoma, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed DLBCL, not otherwise specified (NOS)
  • (disease that has recurred following a response that lasted ≥ 6 months after completion of the last ) or refractory ( disease that did not respond to or that progressed \< 6 months after completion of the last line of therapy) disease
  • At least one prior line of systemic therapy
  • Participants who have failed only one prior line of therapy must not be a candidate for high-dose chemotherapy followed by stem cell transplant (ASCT)
  • At least one bi-dimensionally measurable (> 1.5 cm) nodal lesion, or one bi-dimensionally measurable (> 1 cm) extranodal lesion, as measured on CT scan
  • (ECOG) Performance Status of 0, 1, or 2

Exclusion criteria

Exclusion Criteria:

  • Prior enrollment in Study GO41944 (STARGLO; NCT04408638)
  • Participant has failed only one and is a candidate for stem cell transplantation
  • History of transformation of indolent disease to DLBCL
  • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B-cell lymphoma NOS, as defined by 2016 WHO guidelines
  • Primary mediastinal B-cell lymphoma
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
  • Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
  • Prior treatment with gemcitabine or oxaliplatin
  • Peripheral neuropathy or paresthesia assessed to be Grade >/= 2 according to v5.0 at enrollment
  • Treatment with radiotherapy, chemotherapy, immunotherapy, therapy, or any agent for the purposes of treating cancer within 2 weeks prior to first study treatment
  • Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment
  • Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma
  • Prior CNS involvement that has been definitively treated and confirmed via MRI or cerebrospinal fluid analysis to be in complete remission is permissible
  • Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
  • History of other primary , with exceptions defined by the protocol
  • Significant or extensive cardiovascular disease, or significant pulmonary disease
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (exclusing fungal infections of nail beds) at study enrollment or any major episode of infection within 4 weeks prior to the first study treatment
  • Documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 6 months of first study treatment, or positive SARS-CoV-2 test within 7 days prior to enrollment
  • Suspected or latent tuberculosis
  • Positive test results for (HBV) or (HCV)
  • Known or suspected chronic active Epstein-Barr viral infection
  • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
  • Known history of progressive multifocal leukoencephalopathy
  • Prior solid organ transplantation
  • Prior allogenic stem cell transplant
  • Active disease requiring treatment
  • Prior treatment with systemic immunosuppressive medications within 4 weeks prior to first dose of study treatment
  • Ongoing systemic use which, in the opinion of the investigator, puts the patient at increased risk of steroid-related iatrogenic adrenal insufficiency
  • Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis
  • history of cirrhotic liver disease
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Gemcitabine + Glofitamab + Oxaliplatin

    Participants will receive a single dose of intravenous (IV) obinutuzumab pretreatment 7 days prior to the first dose of glofitamab, followed by up to 8 cycles of glofitamab + gemcitabine + oxaliplatin. This will be followed by up to 4 cycles of glofitamab monotherapy, for a total of up to 12 cycles of glofitamab (cycle length = 21 days).

    Drug: Glofitamab · Drug: Tocilizumab · Drug: Obinutuzumab · Drug: Gemcitabine · Drug: Oxaliplatin

Interventions

  • Participants will receive IV glofitamab for up to 12 cycles (cycle length = 21 days)

  • Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)

  • Participants will receive IV obinutuzumab pretreatment

  • Participants will receive IV gemcitabine for up to 8 cycles (cycle length = 21 days)

  • Participants will receive IV oxaliplatin for up to 8 cycles (cycle length = 21 days)

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Up to 3 years

  2. Complete response (CR) rate

    Time frame: Up to 3 years

Secondary outcomes

  1. Objective response rate (ORR)

    Time frame: Up to 3 years

  2. Duration of response (DOR)

    Time frame: From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 3 years)

  3. Duration of CR

    Time frame: From the first occurrence of a documented CR to disease progression or death from any cause, whichever occurs first (up to 3 years)

  4. Progression-free survival (PFS)

    Time frame: From enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 3 years)

  5. Overall Survival (OS)

    Time frame: From enrollment to date of death from any cause (up to 3 years)

  6. Serum concentration of glofitamab

    Time frame: Up to 3 years

  7. Incidence of anti-drug antibodies to glofitamab

    Time frame: Baseline up to 3 years

07

Study locations

9 sites
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's planned 22 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 2, 2024
StartActual
Apr 28, 2025
Primary completionEst.
Mar 22, 2027
CompletionEst.
Mar 22, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Sites
9 sites removed
Show 9 removed
  • UC San Diego Moores Cancer Center · La Jolla, United States
  • Saddleback Memorial Medical Center · Laguna Hills, United States
  • Hoag Memorial Hospital · Newport Beach, United States
  • Georgetown University · Washington D.C., United States
  • Winship Cancer Institute of Emory University · Atlanta, United States
  • Walter Reed National Military Medical Center · Bethesda, United States
  • Christus Health - Christus St. Vincent Regional Medical Center · Santa Fe, United States
  • East Carolina University · Greenville, United States
  • Renovatio Clinical - El Paso · El Paso, United States
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Active, not recruiting
    9 sites removed
    Show 9 removed
    • UC San Diego Moores Cancer Center · La Jolla, United States
    • Saddleback Memorial Medical Center · Laguna Hills, United States
    • Hoag Memorial Hospital · Newport Beach, United States
    • Georgetown University · Washington D.C., United States
    • Winship Cancer Institute of Emory University · Atlanta, United States
    • Walter Reed National Military Medical Center · Bethesda, United States
    • Christus Health - Christus St. Vincent Regional Medical Center · Santa Fe, United States
    • East Carolina University · Greenville, United States
    • Renovatio Clinical - El Paso · El Paso, United States
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06624085
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 2, 2024
Start date
Apr 28, 2025
Primary completion
Mar 22, 2027 (estimated)
Completion
Mar 22, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glofitamab · Gemcitabine · Oxaliplatin

Start the discussion